Opinion Review
Copyright ©The Author(s) 2022.
World J Cardiol. Jun 26, 2022; 14(6): 329-342
Published online Jun 26, 2022. doi: 10.4330/wjc.v14.i6.329
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Complementary mechanism of action of SGLT-2 inhibitor and GLP-1 receptor agonist dual therapy.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 PRISMA flow diagram for randomized controlled trials chosen for meta-analysis. RCT: Randomized controlled trial.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Three-point major adverse cardiovascular event outcome with GLP-1 receptor agonist plus SGLT-2 inhibitor dual therapy or GLP-1 receptor agonists or SGLT-2 inhibitors vs placebo: A meta-analysis of five cardiovascular outcome trials.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Heart failure hospitalization outcome with GLP-1 receptor agonist plus SGLT-2 inhibitor dual therapy or GLP-1 receptor agonists or SGLT-2 inhibitors vs placebo: A meta-analysis of two cardiovascular outcome trials.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Renal outcome with GLP-1 receptor agonist plus SGLT-2 inhibitor dual therapy or GLP-1 receptor agonists or SGLT-2 inhibitors vs placebo: A meta-analysis of two cardiovascular outcome trials.